Why are not all eligible CML patients willing to attempt TKI discontinuation?

Autoři

ŽÁČKOVÁ Daniela

Rok publikování 2023
Druh Vyžádané přednášky
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Popis A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info